Oramed Pharmaceuticals earnings were $43.9M for the trailing 12 months ending Sep 30, 2025, with 836.4% growth year over year. The latest ORMP earnings report on Sep 30, 2025 announced Q3 2025 earnings of $48.4M, up 264.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ORMP reported annual earnings of -$19.1M, with -445% growth.
ORMP past earnings growth
How has ORMP's earnings growth performed historically?
Oramed Pharmaceuticals Earnings Reports & History FAQ
What were Oramed Pharmaceuticals's earnings last quarter?
On ORMP's earnings call on Invalid Date, Oramed Pharmaceuticals (NASDAQ: ORMP) reported Q3 2025 earnings per share (EPS) of $1.16, up 341.67% year over year. Total ORMP earnings for the quarter were $48.40 million. In the same quarter last year, Oramed Pharmaceuticals's earnings per share (EPS) was -$0.48.
Is Oramed Pharmaceuticals profitable or losing money?
As of the last Oramed Pharmaceuticals earnings report, Oramed Pharmaceuticals is currently profitable. Oramed Pharmaceuticals's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $43.85 million, a 882.13% increase year over year.
What was ORMP's earnings growth in the past year?
As of Oramed Pharmaceuticals's earnings date in Invalid Date, Oramed Pharmaceuticals's earnings has grown 836.36% year over year. This is 778.21 percentage points higher than the US Biotechnology industry earnings growth rate of 58.15%. ORMP earnings in the past year totalled $43.85 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.